ラニビズマブの世界市場レポート 2025年

ラニビズマブの市場規模は、今後数年間で安定した成長が見込まれます。2029年にはCAGR4.3％で33億米ドルに成長します。予測期間の成長は、研究開発の進行、バイオシミラーの導入、併用療法への注目の高まり、遠隔眼科の成長、ラニビズマブの適応拡大、有利な償還政策などに起因すると考えられます。予測期間における主な動向としては、バイオテクノロジーの進歩、ドラッグデリバリーシステムの技術的進歩、個別化医療へのシフト、眼科領域における人工知能の利用の増加、長時間作用型製剤の開発、患者中心のケアモデルの台頭などが挙げられます。

眼疾患の有病率の増加は、今後数年間のラニビズマブ市場の拡大を促進すると予想されます。眼疾患には、目に影響を及ぼし、視力障害や目の健康障害につながるさまざまな疾患が含まれます。これらの疾患の発生率の増加は、人口の高齢化、ライフスタイルの変化、糖尿病などの慢性疾患の増加などの要因に起因しています。ラニビズマブは加齢黄斑変性症や糖尿病性網膜症などの治療に使用され、眼病が蔓延する中でさらなる視力低下を防ぐのに役立っています。例えば、2023年8月、世界保健機関（WHO）は、世界で約22億人が近見または遠見の視力障害に苦しんでいると報告しました。その結果、眼疾患の有病率の増加がラニビズマブの需要を牽引すると予想されます。

ラニビズマブ市場の主なプレーヤーは、網膜障害患者の視力低下に対処し予防するために、ラニビズマブのバイオシミラーなど、費用対効果の高い治療薬の開発に注力しています。ラニビズマブのバイオシミラーとは、オリジナルのラニビズマブと非常に類似しているが、別のブランド名で販売されている生物学的製剤を指し、同等の有効性と安全性プロファイルを維持しながら、より経済的な代替品を提供します。例えば、Formycon AGとBioeq AGは、ルセンティス（ラニビズマブ）のバイオシミラーであるFYB201を2024年4月にカナダとスイスで発売すると発表しました。RanoptoおよびRanivisioという商品名で、それぞれカナダ保健省とスイスメディック社から販売許可を得て発売されるこの製品は、重篤な網膜疾患に対する有効で手ごろな価格の新たな治療選択肢を提供します。すでに米国や欧州各地の患者にとって費用対効果の高い治療選択肢であることが証明されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ラニビズマブ PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のラニビズマブ市場：成長率分析
• 世界のラニビズマブ市場の実績：規模と成長, 2019-2024
• 世界のラニビズマブ市場の予測：規模と成長, 2024-2029, 2034F
• 世界ラニビズマブ総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のラニビズマブ市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 使い捨てプレフィルドシリンジ
• 使い捨てガラスバイアル
• 世界のラニビズマブ市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 滲出型加齢黄斑変性（AMD）
• 糖尿病網膜症（DR）
• 糖尿病黄斑浮腫（DME）
• 近視性脈絡膜新生血管（MCNV）
• 網膜静脈閉塞症（RVO）
• 世界のラニビズマブ市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• その他の流通チャネル
• 世界のラニビズマブ市場、使い捨てプレフィルドシリンジのサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 0.3mlシリンジ
• 0.5mlシリンジ
• 1mlシリンジ
• その他のボリュームバリエーション
• 世界のラニビズマブ市場使い捨てガラスバイアルのサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 0.3Mgまたは0.05 mlバイアル
• 1.0Mgまたは0.1mlバイアル
• 2.0Mgまたは0.2mlバイアル
• その他のボリュームバリエーション

第7章 地域別・国別分析

• 世界のラニビズマブ市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のラニビズマブ市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ラニビズマブ市場：競合情勢
• ラニビズマブ市場：企業プロファイル
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Biogen Inc
• Sun Pharmaceutical Industries Ltd.
• Stada Arzneimittel AG
• Genentech Inc.
• Dr Reddy's Laboratories Ltd
• Cipla Limited
• Samsung Biologics Co Ltd
• Lupin Limited
• Biocon Limited
• Celltrion Healthcare Co Ltd
• Glenmark Pharmaceuticals Limited
• Enzene Biosciences Ltd
• Coherus BioSciences Inc
• Amman Pharmaceutical Industries
• Formycon AG

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ラニビズマブ市場2029：新たな機会を提供する国
• ラニビズマブ市場2029：新たな機会を提供するセグメント
• ラニビズマブ市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Ranibizumab is a recombinant humanized monoclonal antibody fragment designed to inhibit vascular endothelial growth factor A (VEGF-A) activity in treating various retinal conditions. It works by reducing abnormal blood vessel growth and leakage in the eye. Its advantage lies in targeted delivery via intravitreal injection, minimizing systemic side effects while preserving and potentially improving vision.

The main types of ranibizumab include single-use prefilled syringes and single-use glass vials. Single-use ranibizumab syringes are intended for one-time use, filled with the appropriate dosage before distribution, and disposed of after a single injection. They are used in conditions such as wet age-related macular degeneration (AMD), diabetic retinopathy (DR), diabetic macular edema (DME), myopic choroidal neovascularization (MCNV), and retinal vein occlusion (RVO). These are distributed through channels such as hospital pharmacies, online pharmacies, and others.

The ranibizumab market research report is one of a series of new reports from the business research company that provides ranibizumab market statistics, including ranibizumab industry global market size, regional shares, competitors with an ranibizumab market share, detailed ranibizumab market segments, market trends and opportunities, and any further data you may need to thrive in the ranibizumab industry. This ranibizumab market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ranibizumab market size has grown steadily in recent years. It will grow from $2.66 billion in 2024 to $2.78 billion in 2025 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to the expansion of clinical trials in emerging markets, the increasing prevalence of age-related macular degeneration (AMD), growing awareness about retinal diseases, the high incidence of diabetic retinopathy, government initiatives, and funding, and rising healthcare expenditure.

The ranibizumab market size is expected to see steady growth in the next few years. It will grow to $3.3 billion in 2029 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to ongoing research and development, the introduction of biosimilars, an increasing focus on combination therapies, growth in teleophthalmology, expanding indications for ranibizumab, and favorable reimbursement policies. Major trends in the forecast period include advancements in biotechnology, technological advancements in drug delivery systems, a shift towards personalized medicine, the increasing use of artificial intelligence in ophthalmology, the development of longer-acting formulations, and a rise in patient-centric care models.

The growing prevalence of eye diseases is expected to drive the expansion of the ranibizumab market in the coming years. Eye diseases include various conditions that affect the eyes and can lead to vision impairment and compromised eye health. The rising incidence of these conditions is attributed to factors such as aging populations, lifestyle changes, and a rise in chronic diseases like diabetes. Ranibizumab is used to treat conditions like age-related macular degeneration and diabetic retinopathy, helping to prevent further vision loss in the context of increasing eye disease prevalence. For example, in August 2023, the World Health Organization (WHO) reported that approximately 2.2 billion people worldwide suffer from near or distance vision impairment. As a result, the growing prevalence of eye diseases is expected to drive the demand for ranibizumab.

Key players in the ranibizumab market are focusing on developing cost-effective therapies, such as biosimilars of ranibizumab, to address and prevent vision loss in patients with retinal disorders. A biosimilar of ranibizumab refers to a biologic medication highly similar to the original ranibizumab but marketed under a different brand name, providing a more economical alternative while maintaining comparable efficacy and safety profiles. For instance, Formycon AG and Bioeq AG announced the commercial release of FYB201, a biosimilar to Lucentis (Ranibizumab), in Canada and Switzerland in April 2024. This launch, under the brand names Ranopto and Ranivisio, following marketing authorization from Health Canada and Swissmedic respectively, offers a new, effective, and affordable treatment option for severe retinal diseases. It has already proven to be a cost-effective treatment choice for patients in the USA and various parts of Europe.

In March 2024, Sandoz Group AG acquired the CIMERLI business from Coherus BioSciences to bolster its position in the biosimilar market, particularly in ophthalmology. This move leverages Coherus BioSciences' expertise in developing biosimilar versions of medications such as Ranibizumab, used in treating eye diseases. Coherus BioSciences, a US-based biopharmaceutical company, focuses on developing biosimilar versions of medications such as Ranibizumab.

Major companies operating in the ranibizumab market are F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Teva Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc., Biogen Inc, Sun Pharmaceutical Industries Ltd., Stada Arzneimittel AG, Genentech Inc., Dr Reddy's Laboratories Ltd, Cipla Limited, Samsung Biologics Co Ltd, Lupin Limited, Biocon Limited, Celltrion Healthcare Co Ltd, Glenmark Pharmaceuticals Limited, Enzene Biosciences Ltd, Coherus BioSciences Inc, Amman Pharmaceutical Industries, Formycon AG, Intas Pharmaceuticals Ltd, Alvotech, Xbrane Biopharma AB

North America was the largest region in the ranibizumab market in 2024 The regions covered in the ranibizumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ranibizumab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ranibizumab market consists of sales of biosimilars, intravitreal injections, and compounded formulations. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ranibizumab Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ranibizumab market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ranibizumab ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ranibizumab market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Single Use Prefilled Syringe; Single Use Glass Vial
• 2) By Application: Wet Age Related Macular Degeneration (AMD); Diabetic Retinopathy (DR); Diabetic Macular Edema (DME); Myopic Choroidal Neovascularization (MCNV); Retinal Vein Occlusion (RVO)
• 3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Single Use Prefilled Syringe: 0.3 Ml Syringe; 0.5 Ml Syringe; 1 Ml Syringe; Other Volume Variants
• 2) By Single Use Glass Vial: 0.5 Mg Or 0.05 Ml Vial; 1.0 Mg Or 0.1 Ml Vial; 2.0 Mg Or 0.2 Ml Vial; Other Volume Variants
• Companies Mentioned: F. Hoffmann-La Roche AG; Bayer AG; Novartis AG; Teva Pharmaceutical Industries Ltd; Regeneron Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Ranibizumab Market Characteristics

3. Ranibizumab Market Trends And Strategies

4. Ranibizumab Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Ranibizumab Growth Analysis And Strategic Analysis Framework

• 5.1. Global Ranibizumab PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Ranibizumab Market Growth Rate Analysis
• 5.4. Global Ranibizumab Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Ranibizumab Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Ranibizumab Total Addressable Market (TAM)

6. Ranibizumab Market Segmentation

• 6.1. Global Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single Use Prefilled Syringe
• Single Use Glass Vial
• 6.2. Global Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Wet Age Related Macular Degeneration (AMD)
• Diabetic Retinopathy (DR)
• Diabetic Macular Edema (DME)
• Myopic Choroidal Neovascularization (MCNV)
• Retinal Vein Occlusion (RVO)
• 6.3. Global Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Online Pharmacies
• Other Distribution Channels
• 6.4. Global Ranibizumab Market, Sub-Segmentation Of Single Use Prefilled Syringe, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 0.3 Ml Syringe
• 0.5 Ml Syringe
• 1 Ml Syringe
• Other Volume Variants
• 6.5. Global Ranibizumab Market, Sub-Segmentation Of Single Use Glass Vial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 0.5 Mg Or 0.05 Ml Vial
• 1.0 Mg Or 0.1 Ml Vial
• 2.0 Mg Or 0.2 Ml Vial
• Other Volume Variants

7. Ranibizumab Market Regional And Country Analysis

• 7.1. Global Ranibizumab Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Ranibizumab Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Ranibizumab Market

• 8.1. Asia-Pacific Ranibizumab Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Ranibizumab Market

• 9.1. China Ranibizumab Market Overview
• 9.2. China Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Ranibizumab Market

• 10.1. India Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Ranibizumab Market

• 11.1. Japan Ranibizumab Market Overview
• 11.2. Japan Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Ranibizumab Market

• 12.1. Australia Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Ranibizumab Market

• 13.1. Indonesia Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Ranibizumab Market

• 14.1. South Korea Ranibizumab Market Overview
• 14.2. South Korea Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Ranibizumab Market

• 15.1. Western Europe Ranibizumab Market Overview
• 15.2. Western Europe Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Ranibizumab Market

• 16.1. UK Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Ranibizumab Market

• 17.1. Germany Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Ranibizumab Market

• 18.1. France Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Ranibizumab Market

• 19.1. Italy Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Ranibizumab Market

• 20.1. Spain Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Ranibizumab Market

• 21.1. Eastern Europe Ranibizumab Market Overview
• 21.2. Eastern Europe Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Ranibizumab Market

• 22.1. Russia Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Ranibizumab Market

• 23.1. North America Ranibizumab Market Overview
• 23.2. North America Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Ranibizumab Market

• 24.1. USA Ranibizumab Market Overview
• 24.2. USA Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Ranibizumab Market

• 25.1. Canada Ranibizumab Market Overview
• 25.2. Canada Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Ranibizumab Market

• 26.1. South America Ranibizumab Market Overview
• 26.2. South America Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Ranibizumab Market

• 27.1. Brazil Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Ranibizumab Market

• 28.1. Middle East Ranibizumab Market Overview
• 28.2. Middle East Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Ranibizumab Market

• 29.1. Africa Ranibizumab Market Overview
• 29.2. Africa Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Ranibizumab Market Competitive Landscape And Company Profiles

• 30.1. Ranibizumab Market Competitive Landscape
• 30.2. Ranibizumab Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Teva Pharmaceutical Industries Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Ranibizumab Market Other Major And Innovative Companies

• 31.1. Biogen Inc
• 31.2. Sun Pharmaceutical Industries Ltd.
• 31.3. Stada Arzneimittel AG
• 31.4. Genentech Inc.
• 31.5. Dr Reddy's Laboratories Ltd
• 31.6. Cipla Limited
• 31.7. Samsung Biologics Co Ltd
• 31.8. Lupin Limited
• 31.9. Biocon Limited
• 31.10. Celltrion Healthcare Co Ltd
• 31.11. Glenmark Pharmaceuticals Limited
• 31.12. Enzene Biosciences Ltd
• 31.13. Coherus BioSciences Inc
• 31.14. Amman Pharmaceutical Industries
• 31.15. Formycon AG

32. Global Ranibizumab Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Ranibizumab Market

34. Recent Developments In The Ranibizumab Market

35. Ranibizumab Market High Potential Countries, Segments and Strategies

• 35.1 Ranibizumab Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Ranibizumab Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Ranibizumab Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer